Skip to content

Deep Brain Stimulation for the Treatment of Obesity

Deep Brain Stimulation For Morbid, Treatment-Refractory, Obesity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01512134
Enrollment
3
Registered
2012-01-19
Start date
2012-01-31
Completion date
2016-11-30
Last updated
2017-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity, DBS

Brief summary

The purpose of this clinical study is to investigate the safety and efficacy of deep brain stimulation (DBS) as a treatment option for obesity.

Detailed description

The purpose of this clinical study is to investigate the safety and efficacy of deep brain stimulation (DBS) as a treatment option in the management of severe, treatment refractory, morbid obesity.

Interventions

DEVICEDeep Brain Stimulation Device

Deep brain stimulation surgery

Sponsors

Ali Rezai, MD
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* At least 24 months post Roux-en-Y gastric bypass surgery without evidence of a sustained improvement in BMI after gastric bypass surgery for at least 6 months. * Participant is willing to comply with all follow-up evaluations at the specified times * Participant is able to provide informed consent * Fluent in English

Exclusion criteria

* Medical contraindications for general anesthesia, craniotomy, or DBS surgery * Evidence of neurological disorders, e.g., multiple sclerosis, Parkinson's disease and ischemic stroke, or severe brain atrophy or the presence of subdural hygromas or subdural hematomas. * Severe cardiovascular, pulmonary, renal, liver, hematological disease, severe coagulopathy, acute infectious process

Design outcomes

Primary

MeasureTime frameDescription
Percentage of excess weight loss2 yearsThe primary outcome measure at the conclusion of the study will be percent of excess weight loss (EWL).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026